Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
Rink L, Slupianek A, Stoklosa T, Nieborowska-Skorska M, Urbanska K, Seferynska I, Reiss K, Skorski T. Rink L, et al. Among authors: seferynska i. Blood. 2007 Jul 15;110(2):651-60. doi: 10.1182/blood-2006-08-042630. Epub 2007 Apr 12. Blood. 2007. PMID: 17431132 Free PMC article.
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T. Bolton-Gillespie E, et al. Among authors: seferynska i. Blood. 2013 May 16;121(20):4175-83. doi: 10.1182/blood-2012-11-466938. Epub 2013 Mar 29. Blood. 2013. PMID: 23543457 Free PMC article.
The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.
Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, Seferynska I, Stoklosa T, Koromilas AE, Piwocka K. Kusio-Kobialka M, et al. Among authors: seferynska i. Cell Cycle. 2012 Nov 1;11(21):4069-78. doi: 10.4161/cc.22387. Epub 2012 Oct 24. Cell Cycle. 2012. PMID: 23095523 Free PMC article.
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T. Nieborowska-Skorska M, et al. Among authors: seferynska i. J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8. J Clin Invest. 2017. PMID: 28481221 Free PMC article.
Differential expression of BIRC family genes in chronic myeloid leukaemia--BIRC3 and BIRC8 as potential new candidates to identify disease progression.
Glodkowska-Mrowka E, Solarska I, Mrowka P, Bajorek K, Niesiobedzka-Krezel J, Seferynska I, Borg K, Stoklosa T. Glodkowska-Mrowka E, et al. Among authors: seferynska i. Br J Haematol. 2014 Mar;164(5):740-2. doi: 10.1111/bjh.12663. Epub 2013 Nov 25. Br J Haematol. 2014. PMID: 24266799 Free article. No abstract available.
42 results